I review some of the literature concerning antithrombotic therapy in coronary artery disease. The beneficial effects shown are compatible with the unitary hypothesis of thrombosis as a fundamental of cardiovascular risk. The therapeutic approach is limited by the haemorrhagic risk produced by most antithrombotic therapies. A search should therefore be made for antithrombotic therapies without this risk, of which serotonin antagonism appears to be the most promising at present.
FusterVGriggsTR: Porcine von Willebrand disease: Implications for the pathophysiology of atherosclerosis and thrombosis. In Progress in Hemostasis and Thrombosis. Grune & Stratton; 1986:159–183. Acritical test of the hypothesis that thrombosis is a final common pathway in atherogenesis.
2.
De BoerLWVFoltsJD: Garlic extract prevents acute platelet thrombus formation in stenosed canine coronary arteriesAm Heart J1989, 117:973–975.
3.
KellerJWFoltsJD: Relative effects of cigarette smoke and ethanol on acute platelet thrombus formation in stenosed canine coronary arteriesCardiovasc Res1988, 22:73–78.
4.
MitropoulosKA: Lipoprotein metabolism and thrombosisCurr Opin Lipidol1994, 5:227–235.
5.
ClarkLT: Atherogenesis and thrombosis: Mechanisms, pathogenesis and therapeutic implicationsAm Heart J1992, 123:1106–1109.
6.
CairnsJHirschJLewisHResnekovLThérouxP: Antithrombotic agents in coronary artery diseaseChest1992, 102:456S–481S. Comprehensivereview of antithrombotic therapy up to 1992.
7.
BizzozeroJ: Uber einer neuen Formbestandtheil des Blutes und dessen Rolle ei der Thrombose und der BlutgerinnungVirchows Arch1882, 90:261–332.
8.
RossR: The pathogenesis of atherosclerosis – an updateN Engl J Med1986, 314:488–500.
9.
FusterVBadimonLCohenMAmbroseJABadimonJJChesebroJ: Insights into the pathogenesis of acute ischemic syndromesCirculation1988, 77:1213–1220.
10.
WillersonJTGolinoPEidtJCampbellWBBujaM: Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implicationsCirculation1989, 80:198–205.
11.
FalkE: Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusionCirculation1985, 71:699–708.
12.
RidkerPMMansonJEGazianoMBuringJEHennekensCH: Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trialAnn Intern Med1991, 114:835–839.
13.
ChesebroJHWebsterMWISmithHCFryeRHolmesDRReederGS: Antiplatelet therapy in coronary disease progression: Reduced infarction and new lesion formation [abstract]Circulation1989, 80 (suppl II):II266.
14.
LewisHDDavisJWArchibaldDGSteinkeWESmithermanTCDohertyJE: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration cooperative studyN Engl J Med1983, 309:396–403.
15.
GroupRISC: Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery diseaseLancet1990, 336:827–830.
16.
CairnsJAGentMSingerJFinnieKJFroggartGMHolderDA: Aspirin, sulfinpyrazone, or both in unstable angina results of a Canadian multicenter trialN Engl J Med1985, 313:1369–1375.
17.
ThérouxPOuimetHMcCansJLatourJGJolyPLevyG: Aspirin, heparin, or both to treat acute unstable anginaN Engl J Med1988, 319:1105–1111.
18.
PetoRGrayRCollinsRWheatleyKHennekensCJamrozikK: Randomized trial of prophylactic daily aspirin in British male doctorsBMJ1988, 296:313–316.
19.
WillardJELangeRAHillisLD: The use of aspirin in ischemic heart disease [review]N Engl J Med1992, 327:175–181.
20.
Antiplatelet Trialist's Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ1994, 308:81–106. Ameta-analysis of all antiplatelet trials to the end of 1992.
21.
Juul-MöllerSEdvardssonNJahnmatzBRosenASørensenSÖnblusR: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectorisLancet1992, 340:1421–1425.
22.
Antiplatelet Trialist's Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapyBMJ1994, 308:159–168.
23.
Antiplatelet Trialist's Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patientsBMJ1994, 308:236–245.
24.
WattsISWhartonKAWhiteBPLumleyP: Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: Comparison of anti-aggregatory efficacy in human plateletsBr J Pharmacol1991, 102:497–505.
25.
McAuliffeSJGSnowHMSmithCTTNobleMIM: Interaction between the effects of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetized dogBr J Pharmacol1993, 109:405–410.
26.
FoltsJDRoweGG: Epinephrine potentiation of in-vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteriesThromb Res1988, 50:516–518.
27.
FiddlerGILumleyP: Preliminary clinical studies with thromboxane synthetase inhibitors and thromboxane receptor blockersCirculation1990, 81:I69–I78.
28.
HoetBFalconCDe ReysSArmontJDeckmynHVermeylenJ: R68070, a combined thromboxane endoperoxide receptor antagonist and thromboxane synthetase inhibitor, inhibits human platelet activation in vitro and in vivo: A comparison with aspirinBlood1991, 75:646–653.
29.
TimmermansCVrolixMvan HeackeJStammenFPiessensJVercammerE: Ridogrel in the setting of percutaneous transluminal coronary angioplastyAm J Cardiol1990, 68:463–468.
GershlickAH: Principles of platelet inhibitory therapy – where we stood in 1993Eur Heart J1994, 15:149–155. Anin-depth examination of the principles underlying antiplatelet therapy.
32.
BelcherPRDrake-HollandAJNobleMIM: Antagonism of the platelet 5HT2 receptor in the presence of thrombolysisInt J Cardiol1994, 43:11–20.
33.
GoldHKCollerBSYasudaTSaitoTFallonJTGuerreroJL: Rapid and sustained coronary artery recanalization with combined bolus injection of GPIIb/IIIa antibody in a dog modelCirculation1988, 77:670–677.
34.
CollerBSFoltsJDSmithSRScudderLEJordanR: Abolition of in-vivo platelet thrombus formation in primates with monoclonal antibodiesCirculation1989, 80:1766–1774.
35.
MoreRSBrackMJUnderwoodMPringleSde BonoDPGershlickAH: Development of an antithrombotic conjugate with powerful antiplatelet and fibrinolytic properties which can be localised to damaged endotheliumBr Heart J1993, 69:49.
36.
BadimonLBadimonJJ: Mechanism of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow at the apex of stenotic severely injured vessel wall: Experimental study in the pig modelJ Clin Invest1990, 84:1341–1344.
37.
PragerNATorr-BrownSRSobelBEAbendscheinDR: Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and plateletsJ Am Coll Cardiol1993, 22:296–301.
38.
GUSTO IIa: I. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromesCirculation1994, 90:1631–1637.
39.
SmithPArnesenHHolmeI: The effect of warfarin on mortality and reinfarction after myocardial infarctionN Engl J Med1990, 323:147–152.
40.
BelcherPRDrake-HollandAJHyndJNobleMIM: Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dogCardiovasc Res1992, 26:292–296.
41.
NobleMIMDrake-HollandAJ: Evidence for a role of serotonin in initiation of coronary arterial thrombosis in dog and manClin Physiol Biochem1990, 8 (suppl 3):50–55. Areview of the evidence for unique antithrombotic therapy without bleeding complications.
42.
NorrisRMWhiteHDCrossDBWooKSMaslowskiAHCaruanaMP: Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarctionBr Heart J1993, 69:492–495.
43.
MeijerAVerheughtFWAWerterCLieKvan der PolJvan EinigeM: Aspirin versus coumadin in the prevention of reocclusion and recurrent ischaemia after successful thrombolysis: A prospective placebo controlled angiographic study. Results of the APRICOT studyCirculation1993, 87:1524–1530.
44.
WrightRAFlapanAAlbertiKGMLudlamCAFoxKAA: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarctionJ Am Coll Cardiol1994, 24:67–73.
45.
ErnstE: Therapeutic reduction of fibrinogenBlood Coagul Fibrinolysis1994, 5 (suppl 2):16.
46.
KoenigWHoffmeisterHCANehmerCSundMStaubJPWolfC: How do fibrates lower fibrinogen?Blood Coagul Fibrinolysis1994, 5 (suppl 2):16–17.
47.
De MaatMPMKnipscheeerHCKastleleinJJPKluftC: Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemiaBlood Coagul Fibrinolysis1994, 5 (suppl 2):17.
